NUS Develop AI Platform to Identify Personalized Drug Combinations for Myeloma Patients (IMAGE)
Caption
A multidisciplinary team of researchers from the National University of Singapore (NUS) has developed an artificial intelligence (AI) technology platform that could enable doctors to prescribe personalized treatments for myeloma patients.
From left: Professor Chng Wee Joo, Director of the National University Cancer Institute, Singapore and Senior Principal Investigator at the Cancer Science Institute of Singapore, NUS; Dr. Edward Chow, Principal Investigator at the Cancer Science Institute of Singapore, NUS; Dr. Masturah Rashid, recent Ph.D. graduate from NUS and first author of the study; and Professor Dean Ho, Director of the Singapore Institute for Neurotechnology at NUS.
Credit
National University of Singapore
Usage Restrictions
None
License
Licensed content